AMPH · Amphastar Pharmaceuticals, Inc.
$20.91
+0.73 (+3.62%)
At close · Aug 14
Market Cap
$889.47M
Shares
42.54M
Amphastar Pharmaceuticals, Inc. Earnings Call Transcripts
Every quarterly earnings call for Amphastar Pharmaceuticals, Inc. (AMPH) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲7.1%
$120.13M
$15.87M
'22 Q3
22-11-07
▲11.7%
$135.02M
$33.91M
'22 Q4
23-02-28
▲16.3%
$140.02M
$26.03M
'23 Q1
23-05-09
▲18%
$145.71M
$26.12M
'23 Q2
23-08-08
▲50.3%
$180.56M
$49.22M
'23 Q3
23-11-08
▲31.9%
$178.10M
$36.17M
'23 Q4
24-02-28
▲22.7%
$171.84M
$43.18M
'24 Q1
24-05-08
▲25.2%
$182.39M
$37.95M
'24 Q2
24-08-07
▲5.9%
$191.21M
$40.43M
'24 Q3
24-11-06
▲4.7%
$186.52M
$37.96M
'24 Q4
25-02-27
▼0.8%
$170.53M
$25.29M
'25 Q1
25-05-07
▼4.4%
$174.41M
$31.03M
'25 Q2
25-08-07
▲0.3%
$191.84M
$17.35M
'25 Q3
25-11-06
▼1.8%
$183.10M
$24.43M
'25 Q4
26-02-26
▲0.4%
$171.17M
$6.42M
'26 Q1
26-05-07
LATEST
▲5.4%
$183.90M
$30.35M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
Amphastar Second Quarter Earnings Call
Revenue
$183.90M
▲ 5.4% YoY Diluted EPS
$0.67
▲ 4.7% YoY Gross margin
50.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
2026 Jefferies Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Amphastar Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Positive tone
BAQSIMI / glucagon pricing pressure
Primatene MIST branded growth
Full-year 2026 guidance
Revenue
$171.17M
▲ 0.4% YoY Diluted EPS
$0.14
▼ 72.5% YoY Gross margin
41.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Amphastar Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Positive tone
Legacy product headwinds
Capital allocation (buybacks and business development)
BAQSIMI franchise performance and outlook
Revenue
$183.10M*
▼ 1.8% YoY Gross margin
46.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Amphastar Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Confident tone
BAQSIMI growth and ready-to-use glucagon market
Pipeline expansion via Nanjing Anji in-licensing
Margin pressure and cost control
Revenue
$191.84M
▲ 0.3% YoY Diluted EPS
$0.37
▼ 52.6% YoY Gross margin
51.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Amphastar Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Positive tone
Legacy product pricing pressure and competition
BAQSIMI commercial momentum
Pipeline and regulatory milestones
Revenue
$174.41M
▼ 4.4% YoY Diluted EPS
$0.64
▼ 12.3% YoY Gross margin
49.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Amphastar Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Balanced tone
BAQSIMI growth and MannKind partnership
Glucagon and Epinephrine competitive pressure
Tariffs and domestic manufacturing
Revenue
$170.53M
▼ 0.8% YoY Diluted EPS
$0.51
▼ 37% YoY Gross margin
50.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Amphastar Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Positive tone
BAQSIMI growth and MannKind partnership
Pipeline and GDUFA approvals
Primatene MIST branded growth
Revenue
$186.52M*
▲ 4.7% YoY Gross margin
46.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Amphastar Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Positive tone
BAQSIMI franchise and sales force expansion
Primatene Mist growth and expansion
Glucagon and other product competition / pricing pressure
Revenue
$191.21M
▲ 5.9% YoY Diluted EPS
$0.78
▼ 14.3% YoY Gross margin
53.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Amphastar Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Revenue
$182.39M
▲ 25.2% YoY Diluted EPS
$0.73
▲ 49% YoY Gross margin
52.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Amphastar Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Confident tone
Hospital and Other Product Sales
Net Revenue Growth
FTC Orange Book Patent Challenge
Revenue
$171.84M
▲ 22.7% YoY Diluted EPS
$0.81
▲ 62% YoY Gross margin
52.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Amphastar Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Positive tone
BAQSIMI transition
Diabetes portfolio and glucagon
Product launches and pipeline
Revenue
$178.10M*
▲ 31.9% YoY Gross margin
54.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Amphastar Pharmaceuticals, Inc. Q3 FY2023 Earnings Call
Revenue
$180.56M
▲ 50.3% YoY Diluted EPS
$0.91
▲ 203.3% YoY Gross margin
60.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Amphastar Pharmaceuticals, Inc. Q2 FY2023 Earnings Call
Revenue
$145.71M
▲ 18% YoY Diluted EPS
$0.49
▲ 48.5% YoY Gross margin
49.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Amphastar Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Revenue
$140.02M
▲ 16.3% YoY Diluted EPS
$0.50
▲ 6.4% YoY Gross margin
52.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Amphastar Pharmaceuticals, Inc. Q4 FY2022 Earnings Call
Revenue
$135.02M*
▲ 11.7% YoY Gross margin
52.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Amphastar Pharmaceuticals, Inc. Q3 FY2022 Earnings Call
Revenue
$120.13M
▲ 7.1% YoY Diluted EPS
$0.30
▼ 49.2% YoY Gross margin
48.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Amphastar Pharmaceuticals, Inc. Q2 FY2022 Earnings Call
Revenue
$123.47M
▲ 21.4% YoY Diluted EPS
$0.33
▲ 106.2% YoY Gross margin
51.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Amphastar Pharmaceuticals, Inc. Q1 FY2022 Earnings Call
Revenue
$120.37M
▲ 16.8% YoY Diluted EPS
$0.47
▲ 370% YoY Gross margin
46.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Amphastar Pharmaceuticals, Inc. Q4 FY2021 Earnings Call
Revenue
$120.89M*
▲ 26% YoY Gross margin
46.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Amphastar Pharmaceuticals, Inc. Q3 FY2021 Earnings Call
Revenue
$112.20M
▲ 34.5% YoY Diluted EPS
$0.59
▲ 637.5% YoY Gross margin
45.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Amphastar Pharmaceuticals, Inc. Q2 FY2021 Earnings Call
Revenue
$101.66M
▲ 18.5% YoY Diluted EPS
$0.16
Gross margin
46.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Amphastar Pharmaceuticals, Inc. Q1 FY2021 Earnings Call
Revenue
$103.02M
▲ 21.6% YoY Diluted EPS
$0.10
▲ 25% YoY Gross margin
43.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-15
Amphastar Pharmaceuticals, Inc. Q4 FY2020 Earnings Call
Revenue
$95.92M*
▲ 15% YoY Gross margin
38.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-06
Amphastar Pharmaceuticals, Inc. Q3 FY2020 Earnings Call
Revenue
$83.43M
▲ 4.1% YoY Diluted EPS
$0.08
▲ 166.7% YoY Gross margin
43.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Amphastar Pharmaceuticals, Inc. Q2 FY2020 Earnings Call
Revenue
$85.81M
▲ 8.6% YoY Diluted EPS
$0.00
▼ 100% YoY Gross margin
38.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Amphastar Pharmaceuticals, Inc. Q1 FY2020 Earnings Call
Revenue
$84.69M
▲ 6.1% YoY Diluted EPS
$0.08
▲ 300% YoY Gross margin
43.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Amphastar Pharmaceuticals, Inc. Q4 FY2019 Earnings Call
Revenue
$83.38M
▼ 7% YoY Diluted EPS
$-0.02
▼ 150% YoY Gross margin
40.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1297184
CUSIP
03209R103
13F (30d)
191 filings
189 filers
Visit website
Investor relations